Compare GXO & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GXO | KRYS |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | GXO | KRYS |
|---|---|---|
| Price | $53.74 | $246.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $62.00 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 1.0M | 272.8K |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 0.76 | ★ 6.66 |
| Revenue | ★ $12,921,000,000.00 | $373,164,000.00 |
| Revenue This Year | $13.31 | $36.14 |
| Revenue Next Year | $5.86 | $41.80 |
| P/E Ratio | $70.68 | ★ $37.07 |
| Revenue Growth | 16.94 | ★ 54.51 |
| 52 Week Low | $30.46 | $122.80 |
| 52 Week High | $57.99 | $246.94 |
| Indicator | GXO | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 85.32 |
| Support Level | $51.90 | $213.83 |
| Resistance Level | $53.56 | $241.65 |
| Average True Range (ATR) | 1.26 | 7.92 |
| MACD | 0.55 | 2.15 |
| Stochastic Oscillator | 91.88 | 97.04 |
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.